Progressing Admilparant, an LPA1 Antagonist, Through Phase 3 for IPF & PPF: An Update on Progress, Perspectives & Positioning
- Explore the latest developments in the Phase 3 program, including trial design evolution, enrollment strategy, and global rollout progress
- Reflect on key learnings from the Phase 2 study and how they informed the transition to late-stage development
- Discuss how LPA1 antagonism may fit into an increasingly crowded and combinationdriven pulmonary fibrosis treatment landscape